Cargando...
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 ampli...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Lenguaje: | Inglês |
Publicado: |
MDPI AG
2022-03-01
|
Colección: | Current Oncology |
Materias: | |
Acceso en línea: | https://www.mdpi.com/1718-7729/29/4/176 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|